MediLink Therapeutics Entered into Worldwide Collaboration and License Agreement with Roche.

SUZHOU, China, January, 02, 2024-MediLink Therapeutics ("MediLink") announced that it entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody drug conjugate candidate YL211 on January 2, 2024.   MediLink will receive upfront and near-term milestone payments$50 million and potentially $1 billion for additional development, regulatory and commercial milestone payment, as well as tiered royalties on future global annual net sales from Roche. Roche will initiate thePhase I clinical trial of YL211 with MediLink and will take over the further development and commercialization globally of this drug.

YL211 is a next-generation antibody-drug conjugate specifically targeting c-Mesenchymal-epithelial transition factor (c-Met), which belongs to the receptor tyrosine kinase (RTK) family.

For details, please click: https://www.medilinkthera.com/news-details/32